Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lexaria Bioscience ( (LEXX) ) has issued an update.
Lexaria released additional secondary and exploratory results from its 12‑week Phase 1b GLP-1-H24-4 study in Australia, comparing several DehydraTECH-based formulations to oral semaglutide (Rybelsus). Secondary efficacy outcomes showed no statistically significant differences between DehydraTECH arms and Rybelsus in fasting glucose, cholesterol and LDL at week 16, suggesting at least comparable metabolic effects. Body composition analysis indicated that while Rybelsus produced greater overall and fat mass reductions, DehydraTECH-semaglutide was associated with a smaller proportional loss of lean mass, hinting at a potentially more favorable bodyweight quality profile. In addition, the DehydraTECH-cannabidiol arm produced meaningful reductions in blood pressure despite participants not being generally hypertensive, reinforcing Lexaria’s rationale to advance its DHT-CBD program for hypertension, which already has FDA clearance for a Phase 1b study. Pharmacokinetic work revealed assay-related challenges in measuring DehydraTECH-delivered semaglutide via LCMS, though preliminary ELISA testing confirmed measurable semaglutide levels, with broader analysis now underway, underscoring both the promise and technical complexity of the company’s platform as it shapes its 2026 R&D and business development plans.
The most recent analyst rating on (LEXX) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a drug delivery technology company that develops and licenses its patented DehydraTECH platform, designed to enhance the bioavailability and performance of active pharmaceutical ingredients such as GLP-1 agonists and cannabidiol. The company is focused on applications in metabolic disorders, cardiovascular conditions and other therapeutic areas where improved delivery and efficacy of existing drugs can create commercial and clinical advantages.
Average Trading Volume: 650,052
Technical Sentiment Signal: Sell
Current Market Cap: $13.21M
See more insights into LEXX stock on TipRanks’ Stock Analysis page.